| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5514646 | LILLY | Insulin analogs modified at position 29 of the B chain |
May, 2013
(10 years ago) | |
| US5474978 | LILLY | Insulin analog formulations |
Jun, 2014
(9 years ago) | |
Humalog is owned by Lilly.
Humalog contains Insulin Lispro Recombinant.
Humalog has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Humalog are:
- US5514646
- US5474978
Humalog was authorised for market use on 15 November, 2019.
Humalog is available in injectable;injection dosage forms.
Humalog can be used as humalog is an insulin analog that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia.
The generics of Humalog are possible to be released after 12 October, 2015.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NR(NR) | Oct 12, 2015 |
Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient
Market Authorisation Date: 15 November, 2019
Treatment: Humalog is an insulin analog that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia
Dosage: INJECTABLE;INJECTION
HUMALOG family patents
